$343.29
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
Madrigal Pharmaceuticals Insider Trading Activity | NASDAQ:MDGL | Benzinga
Track the latest Madrigal Pharmaceuticals insider trading activity. Stay informed on recent buys, sells, and market impact for Madrigal Pharmaceuticals stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Madrigal Pharmaceuticals Inc Insiders Doing?
At Madrigal Pharmaceuticals Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 5.70K shares worth $1.88M, meanwhile, insiders have report no purchases in the last 30 days.
Notable Recent Insider Buys and Sales
- On January 27, 2025, Robert Waltermire, the company's SENIOR VP, CHIEF PHARMA DEV. sold 103 shares for $335.24 each.
- On January 17, 2025, Shannon Kelley, the company's GENERAL COUNSEL sold 277 shares for $273.41 each.
- On March 12, 2025, Mardi Dier, the company's SVP AND CFO sold 258 shares for $323.04 each.
Ownership Statistics for Madrigal Pharmaceuticals Inc
Shares Outstanding
22.080M
Insider Shares Owned
9.010M
Insider Percentage Owned
40.8%
Institutional Shares Held
12.021M
Institutional Percentage Held
54.4%
| Mar 14, 2025 | FRED CRAVES | DIRECTOR | 0.00 | $205.72 | -$3.80M | SELL-OPTIONS | 0.00% | 371.08K | Mar 12 - Mar 13 | View |
| Mar 12, 2025 | Mardi Dier | SVP AND CFO | -258.00 | $323.04 | -$83.34K | SELL | -2.41% | 10.44K | Mar 10 | View |
| Mar 07, 2025 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 2.06K | $214.41 | -$3.58M | SELL-OPTIONS | 55.28% | 5.79K | Mar 05 | View |
| Mar 05, 2025 | Shannon Kelley | GENERAL COUNSEL | -415.00 | $335.00 | -$139.03K | SELL | -5.39% | 7.29K | Mar 03 | View |
| Mar 05, 2025 | Mardi Dier | SVP AND CFO | -1.96K | $324.96 | -$637.25K | SELL | -22.10% | 6.91K | Mar 03 | View |
| Mar 05, 2025 | Carole Huntsman | CHIEF COMMERCIAL OFFICER | -1.83K | $325.98 | -$597.84K | SELL | -17.57% | 8.60K | Mar 03 | View |
| Mar 04, 2025 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | -1.23K | $341.07 | -$418.49K | SELL | -24.76% | 3.73K | Feb 28 | View |
| Feb 28, 2025 | James Daly | DIRECTOR | 0.00 | $215.18 | -$4.09M | SELL-OPTIONS | 0.00% | 1.91K | Feb 27 | View |
| Feb 28, 2025 | KENNETH BATE | DIRECTOR | 0.00 | $211.35 | -$5.80M | SELL-OPTIONS | 0.00% | 1.91K | Feb 27 | View |
| Jan 27, 2025 | Carole Huntsman | CHIEF COMMERCIAL OFFICER | -347.00 | $335.24 | -$116.33K | SELL | -3.22% | 10.44K | Jan 24 | View |
| Jan 27, 2025 | John William Sibold | PRESIDENT AND CEO | -1.58K | $335.24 | -$531.02K | SELL | -2.83% | 54.30K | Jan 24 | View |
| Jan 27, 2025 | Rebecca Taub | PRES., R&D, AND CMO | -648.00 | $335.24 | -$217.24K | SELL | -0.06% | 1.11M | Jan 24 | View |
| Jan 27, 2025 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | -103.00 | $335.24 | -$34.53K | SELL | -2.04% | 4.96K | Jan 24 | View |
| Jan 17, 2025 | Shannon Kelley | GENERAL COUNSEL | -277.00 | $273.41 | -$75.73K | SELL | -3.47% | 7.71K | Jan 17 | View |
| Jan 17, 2025 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | -442.00 | $273.41 | -$120.85K | SELL | -8.04% | 5.06K | Jan 17 | View |
| Jan 17, 2025 | Rebecca Taub | PRES., R&D, AND CMO | -1.69K | $273.41 | -$461.79K | SELL | -0.15% | 1.11M | Jan 17 | View |
| Dec 05, 2024 | FRED CRAVES | DIRECTOR | -3.60K | $315.31 | -$1.14M | SELL | -22.70% | 12.26K | Dec 03 | View |
| Nov 27, 2024 | FRED CRAVES | DIRECTOR | -3.40K | $350.30 | -$1.19M | SELL | -17.65% | 15.86K | Nov 25 | View |
| Nov 22, 2024 | Carole Huntsman | CHIEF COMMERCIAL OFFICER | -688.00 | $316.92 | -$218.04K | SELL | -6.00% | 10.79K | Nov 21 | View |
| Nov 08, 2024 | Richard Levy | — | 0.00 | $178.68 | -$1.71M | SELL-OPTIONS | 0.00% | 11.01K | Nov 07 | View |
| Nov 05, 2024 | Richard Levy | — | 0.00 | $154.15 | -$1.47M | SELL-OPTIONS | 0.00% | 11.01K | Nov 01 | View |
| Sep 11, 2024 | John William Sibold | PRESIDENT AND CEO | -6.36K | $243.83 | -$1.55M | SELL | -10.22% | 55.89K | Sep 09 | View |
| Jun 18, 2024 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 0.00 | $183.55 | -$366.53K | SELL-OPTIONS | 0.00% | 5.50K | Jun 14 | View |
| Jun 14, 2024 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 0.00 | $186.46 | -$394.16K | SELL-OPTIONS | 0.00% | 5.50K | Jun 12 | View |
| May 23, 2024 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | -1.04K | $231.34 | -$239.67K | SELL | -15.85% | 5.50K | May 21 | View |
| May 16, 2024 | FRED CRAVES | — | 0.00 | $157.95 | -$2.47M | SELL-OPTIONS | 0.00% | 431.36K | May 14 | View |
| Apr 10, 2024 | Rebecca Taub | PRES., R&D, AND CMO | 0.00 | $127.72 | -$632.97K | SELL-OPTIONS | 0.00% | 1.11M | Apr 08 | View |
| Apr 10, 2024 | PAUL FRIEDMAN | — | 0.00 | $127.82 | -$6.22M | SELL-OPTIONS | 0.00% | 841.27K | Apr 08 | View |
| Apr 05, 2024 | Rebecca Taub | PRES., R&D, AND CMO | 0.00 | $126.68 | -$17.32M | SELL-OPTIONS | 0.00% | 1.11M | Apr 03 - Apr 05 | View |
| Apr 05, 2024 | PAUL FRIEDMAN | DIRECTOR | 0.00 | $126.69 | -$17.29M | SELL-OPTIONS | 0.00% | 841.27K | Apr 03 - Apr 05 | View |
| Apr 03, 2024 | Richard Levy | — | 0.00 | $160.70 | -$2.13M | SELL-OPTIONS | 0.00% | 10.30K | Apr 01 | View |
| Apr 03, 2024 | KENNETH BATE | DIRECTOR | 0.00 | $163.54 | -$5.80M | SELL-OPTIONS | 0.00% | 1.20K | Apr 01 - Apr 02 | View |
| Apr 03, 2024 | James Daly | DIRECTOR | 0.00 | $177.60 | -$4.90M | SELL-OPTIONS | 0.00% | 1.20K | Apr 01 - Apr 02 | View |
| Dec 18, 2023 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 0.00 | $161.71 | -$590.32K | SELL-OPTIONS | 0.00% | 5.67K | Dec 14 - Dec 15 | View |
| Dec 14, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 101.79K | $221.20 | $22.52M | BUY | 6.02% | 1.79M | Dec 13 - Dec 14 | View |
| Dec 14, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 34.58K | $218.31 | $7.55M | BUY | 2.08% | 1.70M | Dec 12 | View |
| Dec 14, 2023 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 0.00 | $155.37 | -$512.60K | SELL-OPTIONS | 0.00% | 5.67K | Dec 12 - Dec 13 | View |
| Dec 06, 2023 | Brian J. Lynch | SVP AND GENERAL COUNSEL | 0.00 | $152.58 | -$388.11K | SELL-OPTIONS | 0.00% | 15.53K | Dec 04 - Dec 05 | View |
| Dec 01, 2023 | Brian J. Lynch | SVP AND GENERAL COUNSEL | 0.00 | $137.62 | -$894.23K | SELL-OPTIONS | 0.00% | 15.53K | Nov 29 - Nov 30 | View |
| Nov 21, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 64.35K | $188.47 | $12.13M | BUY | 4.01% | 1.67M | Nov 21 | View |
| Nov 21, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 67.08K | $178.11 | $11.95M | BUY | 4.35% | 1.61M | Nov 17 - Nov 20 | View |
| Nov 15, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 49.39K | $158.13 | $7.81M | BUY | 3.30% | 1.55M | Nov 14 - Nov 15 | View |
| Nov 15, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 107.50K | $146.99 | $15.80M | BUY | 7.72% | 1.50M | Nov 13 - Nov 14 | View |
| Mar 02, 2023 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 0.00 | $180.58 | -$1.85M | SELL-OPTIONS | 0.00% | 5.67K | Feb 28 - Mar 01 | View |
| Jan 19, 2023 | Richard Levy | DIRECTOR | 0.00 | $198.09 | -$4.28M | SELL-OPTIONS | 0.00% | 9.10K | Jan 17 | View |
| Jan 06, 2023 | Brian J. Lynch | SVP AND GENERAL COUNSEL | 0.00 | $187.36 | -$2.48M | SELL-OPTIONS | 0.00% | 530.00 | Jan 03 | View |
| Dec 28, 2022 | Brian J. Lynch | SVP AND GENERAL COUNSEL | 0.00 | $182.98 | -$1.28M | SELL-OPTIONS | 0.00% | 530.00 | Dec 23 | View |
| Dec 28, 2022 | Remy Sukhija | CHIEF COMMERCIAL OFFICER | 0.00 | $167.20 | -$6.42M | SELL-OPTIONS | 0.00% | 0.00 | Dec 23 | View |
| Aug 19, 2020 | BAY CITY CAPITAL LLCBay City Capital Management IV LLCBay City Capital Fund IV LPBAY CITY CAPITAL FUND IV CO INVESMENT FUND LP | — | -30.00K | $109.74 | -$3.29M | SELL | -19.45% | 124.25K | Aug 17 - Aug 19 | View |
| Aug 19, 2020 | Fred B Craves | — | -30.00K | $109.74 | -$3.29M | SELL | -18.42% | 132.88K | Aug 17 - Aug 19 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.